C4 Therapeutics Inc (CCCC)
4.71
+0.47
(+11.08%)
USD |
NASDAQ |
Jun 24, 16:00
4.705
0.00 (0.00%)
After-Hours: 20:00
C4 Therapeutics Revenue (Quarterly): 3.039M for March 31, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 3.039M |
| December 31, 2023 | 3.261M |
| September 30, 2023 | 11.07M |
| June 30, 2023 | 2.664M |
| March 31, 2023 | 3.759M |
| December 31, 2022 | 2.854M |
| September 30, 2022 | 6.754M |
| June 30, 2022 | 13.83M |
| March 31, 2022 | 7.654M |
| December 31, 2021 | 20.08M |
| Date | Value |
|---|---|
| September 30, 2021 | 8.50M |
| June 30, 2021 | 9.781M |
| March 31, 2021 | 7.426M |
| December 31, 2020 | 8.262M |
| September 30, 2020 | 8.447M |
| June 30, 2020 | 9.67M |
| March 31, 2020 | 6.816M |
| December 31, 2019 | 8.209M |
| September 30, 2019 | 5.364M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
2.664M
Minimum
Jun 2023
20.08M
Maximum
Dec 2021
7.760M
Average
7.654M
Median
Mar 2022
Revenue (Quarterly) Benchmarks
| CEL-SCI Corp | -- |
| AIM ImmunoTech Inc | 0.04M |
| IGC Pharma Inc | 0.204M |
| NovaBay Pharmaceuticals Inc | 2.631M |
| Protalix BioTherapeutics Inc | 3.748M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -28.36M |
| Total Expenses (Quarterly) | 32.82M |
| EPS Diluted (Quarterly) | -0.41 |
| Enterprise Value | 65.88M |
| Profit Margin (Quarterly) | -933.2% |
| Earnings Yield | -50.32% |
| Normalized Earnings Yield | -49.35 |